- 作者：Xavier Pivot ; Gilles Romieu ; Marc Debled ; Jean-Yves Pierga ; Pierre Kerbrat ; Thomas Bachelot ; Alain Lortholary ; Marc Espi¨¦ ; Pierre Fumoleau ; Daniel Serin ; Jean-Philippe Jacquin ; Christelle Jouannaud ; Maria Rios ; Sophie Abadie-Lacourtoisie ; Nicole Tubiana-Mathieu ; Laurent Cany ; St¨¦phanie Catala ; David Khayat ; Iris Pauport¨¦ ; Andrew Kramar ; et al.
- 刊名：Lancet Oncology
- 出版年：2013
- 出版时间：July, 2013
- 年：2013
- 卷：14
- 期：8
- 页码：741-748
- 全文大小：358 K
Summary
Background
Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer. However, the optimum duration of treatment has been debated. We did a non-inferiority trial of a shorter exposure of 6 months versus the standard 12 months of trastuzumab for patients with early breast cancer.Methods
We did an open-label, randomised, phase 3 trial in 156 centres in France. Patients with HER2-positive early breast cancer who had received at least four cycles of chemotherapy, had breast-axillary surgery, and had received up to 6 months of trastuzumab (administered by intravenous infusions over 30-90 min every 3 weeks; initial loading dose 8 mg/kg; 6 mg/kg thereafter) before randomisation were eligible. Patients were randomly assigned via central randomisation procedure with web-based software to continue trastuzumab for another 6 months (12 months total duration; control group) or to discontinue trastuzumab at 6 months (6 months total duration; experimental group). Randomisation was stratified by concomitant or sequential administration of trastuzumab with chemotherapy, oestrogen-receptor status, and centre using a minimisation algorithm. The primary endpoint was disease-free survival, with a prespecified non-inferiority margin of 1¡¤15. Analyses were done in the intention-to-treat population. This study is registered at , number .
Findings
1691 patients were randomly assigned to receive 12 months of trastuzumab and 1693 to receive 6 months of trastuzumab; 1690 patients in each group were included in the intention-to-treat analyses. After a median follow-up of 42¡¤5 months (IQR 30¡¤1-51¡¤6), 175 disease-free survival events were noted in the 12-month group and 219 in the 6-month group. 2-year disease-free survival was 93¡¤8 % (95 % CI 92¡¤6-94¡¤9) in the 12-month group and 91¡¤1 % (89¡¤7-92¡¤4) in the 6-month group (hazard ratio 1¡¤28, 95 % CI 1¡¤05-1¡¤56; p=0¡¤29). 119 (93 % ) of the 128 cardiac events (clinical or based on assessment of left ventricular ejection fraction) occurred while patients were receiving trastuzumab. Significantly more patients in the 12-month group experienced a cardiac event than did those in the 6-month group (96 [5¡¤7 % ] of 1690 patients vs 32 [1¡¤9 % ] of 1690 patients, p<0¡¤0001).
Interpretation
After 3¡¤5 years follow-up, we failed to show that 6 months of treatment with trastuzumab was non-inferior to 12 months of trastuzumab. Despite the higher rates of cardiac events, 12 months of adjuvant trastuzmab should remain the standard of care.
Funding
French National Cancer Institute.